Disparities in the COVID-19 pandemic: A clarion call for preventive cardiology

Keith C Ferdinand1, Tina K Reddy1

  • 1Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA 70112, USA.

Insights

COVID-19 disproportionately affected racial/ethnic minorities and those with cardiometabolic conditions. Addressing social injustice and promoting vaccine equity are crucial to reduce COVID-19 deaths and improve health outcomes.

Area of Science:

  • Public Health
  • Epidemiology
  • Health Equity

Background:

  • COVID-19 significantly impacted the US in 2020, ranking as the third leading cause of death.
  • Factors like obesity, hypertension, diabetes, social vulnerability, and socioeconomic status exacerbated COVID-19 hospitalizations and mortality.
  • Disparities in COVID-19 outcomes were evident among older adults, racial/ethnic populations, and individuals experiencing homelessness.

Purpose of the Study:

  • To address the intersection of social injustice, cardiovascular disparities, and increased COVID-19 morbidity and mortality in US racial/ethnic populations.
  • To highlight the role of immunization in mitigating COVID-19's severe impact.
  • To emphasize the importance of vaccine access and overcoming barriers within communities.

Main Methods:

  • This commentary summarizes a keynote lecture presented at the Cardiometabolic Health Congress (CMHC).
  • The lecture focused on the social determinants of health and their impact on cardiometabolic health and infectious disease outcomes.
  • Discussion included strategies for improving vaccine acceptance and uptake.

Main Results:

  • Racial/ethnic populations and individuals with cardiometabolic conditions experienced disproportionately higher rates of COVID-19 morbidity and mortality.
  • Social injustice and systemic inequities were identified as key drivers of these disparities.
  • Vaccine acceptance, uptake, and equitable access were presented as critical interventions.

Conclusions:

  • Addressing social injustice is paramount to reducing cardiovascular and cardiometabolic disparities.
  • Targeted strategies utilizing trusted community leaders are essential to overcome vaccine misconceptions and barriers in racial/ethnic communities.
  • Achieving widespread immunization and equitable vaccine access is vital to combatting the severe consequences of COVID-19.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
393
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
483
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
68
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
79
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
94
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
81